Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.46 |
| ▸ | USP2 | O75604 | 7/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713852 | 0.91 | CYP3A4 (0.46) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| SCHEMBL18886174 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| SCHEMBL21639945 | 0.82 | CYP3A4 (0.57) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| SCHEMBL1190095 | 0.81 | CYP3A4 (0.50) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| SCHEMBL8941890 | 0.79 | CYP3A4 (0.48) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| SCHEMBL70939 | 0.78 | NPSR1 (0.54) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| SCHEMBL31037787 | 0.77 | CYP3A4 (0.53) | CYP3A4CYP2D6ALOX15CYP2C9USP2 | |
| SCHEMBL27272480 | 0.75 | CYP3A4 (0.54) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| Hydrochloric Acid SCHEMBL2961620 | 0.74 | NPSR1 (0.50) | CYP3A4CYP2D6ALOX15NPSR1GPR55 | |
| SCHEMBL17049270 | 0.74 | OPRM1 (0.56) | CYP3A4CYP2D6ALOX15NPSR1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250368666-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025111582-A1 | AZA-TETRACYCLIC OXAZEPINE INHIBITORS OF KRAS-G12D | GENENTECH, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4547656-A1 | INDAZOLE COMPOUNDS | Tyra Biosciences, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024229317-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024138112-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024006897-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2007056221-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| US-5576320-A | 1-heteruarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-11-19 | — | — | US | disclosed |
| US-5565474-A | 1-heteroarylazetidines and -pyrrolidines process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-10-15 | — | — | US | disclosed |
| US-5556861-A | 1,8 benzonaphthyridine derivatives and antimicrobial compositions | LABORATOIRE ROGER BELLON (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| EP-0406112-B1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | disclosed |
| EP-0591030-A2 | 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
| US-5073646-A | Chemical intermediates, microbiocides | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-12-17 | — | — | US | disclosed |
| EP-0406112-A1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368666-A1 | INDAZOLE COMPOUNDS | FGFR1, FGFR3, FGFR2 | CYP3A4 1825/4885CYP2D6 2312/4885ALOX15 2499/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | CYP3A4 35/4885CYP2D6 41/4885ALOX15 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.